Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pneumococcal capsular polysaccharides (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) are the complex carbohydrate structures that form the outermost layer of Streptococcus pneumoniae bacteria (Source: NIH, CDC). These polysaccharides are the primary virulence factors of the pathogen, as they protect the bacteria from host immune recognition and inhibit phagocytosis by neutrophils and macrophages (Source: PubMed, ATCC). There are over 100 known serotypes of S. pneumoniae, but the specific group of seven (4, 6B, 9V, 14, 18C, 19F, and 23F) was historically responsible for the majority of invasive pneumococcal disease (IPD) in children worldwide (Source: CDC, NIH). These polysaccharides serve as the antigenic components in vaccines, most notably the first pneumococcal conjugate vaccine, PCV7 (Source: FDA). When administered, they stimulate the production of serotype-specific antibodies that opsonize the bacteria, allowing the immune system to effectively clear the infection (Source: StatPearls, WHO). While highly effective at reducing disease caused by these specific serotypes, their use has led to 'serotype replacement,' where non-vaccine serotypes fill the ecological niche left by the targeted strains (Source: PubMed).
These polysaccharides act as antigens that stimulate the production of serotype-specific antibodies. In conjugate vaccines (PCVs), the polysaccharides are covalently linked to a carrier protein (such as CRM197), which converts the T-cell independent polysaccharide into a T-cell dependent antigen. This process induces a robust immune response, including the production of high-affinity IgG antibodies and the creation of B-cell memory. These antibodies opsonize the Streptococcus pneumoniae capsule, facilitating its recognition and destruction by phagocytic cells like macrophages and neutrophils (Source: NIH, StatPearls).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pneumococcal capsular polysaccharides (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) (PCV7 antigens).